Biotechnology company earns Best Companies Group honors for the fourth
consecutive year
ARDSLEY, N.Y.--(BUSINESS WIRE)--
Biotechnology leader Acorda Therapeutics, Inc. (Nasdaq:ACOR)
has been named as one of the best
companies in New York to work for, based on an independent survey by
the Best Companies Group (BCG). The award identifies the best employers
in the state, and Acorda was named to the list for the fourth
consecutive year.
Acorda was ranked third among this year’s list of large employers,
defined as employing more than 250 people. The rankings are determined
by feedback from employees about company culture, benefits and overall
job satisfaction.
“When I founded Acorda almost 20 years ago, my goal was to build a
company that would deliver life-changing therapies to patients in need,
and to do so in a culture that embodied teamwork, innovation, open
communication and integrity,” said
Ron Cohen
, M.D., Acorda’s President
and CEO. “Being recognized as one of the best
places to work in New York for the fourth consecutive year affirms
the value that our associates place on this culture.”
“It is fulfilling to work at a company that has brought important new
medicines to market to address neurological diseases and improve
people’s lives,” continued Cohen. “It’s especially rewarding to be doing
so within a culture that recognizes the contributions of each of our
more than 420 associates, and give us a sense of both purpose and fun!”
The Best Places to Work survey was conducted by BCG, an independent
company that manages Best Places to Work programs on state, regional and
national levels. The award is a partnership of the New York State
Society for Human Resource Management (NYS-SHRM), The Business Council
of New York, BCG and Journal Multimedia Corporation.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that improve the lives of people with neurological disorders.
Acorda markets three FDA-approved therapies including: AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to
improve walking in patients with multiple
sclerosis (MS); ZANAFLEX
CAPSULES® (tizanidine hydrochloride) and Zanaflex
tablets, a short-acting drug for the management of spasticity; and Qutenza®
(capsaicin) 8% Patch, for the management of neuropathic pain
associated with postherpetic neuralgia. AMPYRA is marketed outside the
United States as FAMPYRA® (prolonged-release fampridine
tablets) by Biogen Idec under a licensing agreement from Acorda.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is currently developing six
clinical-stage therapies and one preclinical stage therapy that address
a range of disorders including post-stroke deficits, epilepsy, stroke,
peripheral nerve damage, spinal cord injury, neuropathic pain, and heart
failure. For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including Plumiaz (our trade name for Diazepam
Nasal Spray), or any other acquired or in-licensed programs; we may not
be able to complete development of, obtain regulatory approval for, or
successfully market Plumiaz or other products under development; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to successfully
market Fampyra outside of the U.S. and our dependence on our
collaboration partner Biogen Idec in connection therewith; competition,
including the impact of generic competition on Zanaflex Capsules
revenues; failure to protect our intellectual property, to defend
against the intellectual property claims of others or to obtain third
party intellectual property licenses needed for the commercialization of
our products; failure to comply with regulatory requirements could
result in adverse action by regulatory agencies; and the ability to
obtain additional financing to support our operations. These and other
risks are described in greater detail in Acorda Therapeutics' filings
with the Securities & Exchange Commission. Acorda may not actually
achieve the goals or plans described in its forward-looking statements,
and investors should not place undue reliance on these statements.
Forward-looking statements made in this release are made only as of the
date hereof, and Acorda disclaims any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this release.
Source: Acorda Therapeutics